KORU Medical Systems (NASDAQ:KRMD) COO Christopher Pazdan Acquires 5,000 Shares of Stock

KORU Medical Systems, Inc. (NASDAQ:KRMD) COO Christopher Pazdan purchased 5,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $3.88 per share, with a total value of $19,400.00. Following the acquisition, the chief operating officer directly owned 305,131 shares in the company, valued at $1,183,908.28. This represents a 1.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

KORU Medical Systems Price Performance

NASDAQ KRMD opened at $3.83 on Tuesday. The stock has a market capitalization of $175.91 million, a PE ratio of -76.60 and a beta of 0.43. The business has a 50 day simple moving average of $4.22 and a two-hundred day simple moving average of $4.84. KORU Medical Systems, Inc. has a 1-year low of $2.63 and a 1-year high of $6.61.

KORU Medical Systems (NASDAQ:KRMD) last announced its earnings results on Wednesday, May 6th. The company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). The firm had revenue of $11.76 million during the quarter, compared to analysts’ expectations of $11.28 million. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%. On average, analysts anticipate that KORU Medical Systems, Inc. will post -0.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on KRMD shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a report on Tuesday, April 21st. Wall Street Zen cut KORU Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. B. Riley Financial boosted their price objective on KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $6.00 price objective on shares of KORU Medical Systems in a report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Acuitas Investments LLC raised its position in shares of KORU Medical Systems by 89.6% in the 3rd quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock worth $2,923,000 after acquiring an additional 360,594 shares in the last quarter. Simcoe Capital LLC bought a new position in shares of KORU Medical Systems in the 4th quarter worth $3,921,000. Goldman Sachs Group Inc. raised its position in shares of KORU Medical Systems by 189.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after acquiring an additional 158,914 shares in the last quarter. Barclays PLC raised its position in shares of KORU Medical Systems by 8.8% in the 4th quarter. Barclays PLC now owns 67,442 shares of the company’s stock worth $392,000 after acquiring an additional 5,457 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of KORU Medical Systems by 26.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock worth $158,000 after acquiring an additional 5,649 shares in the last quarter. 58.60% of the stock is owned by institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.